Published in J Neuropathol Exp Neurol on September 01, 2001
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (2010) 2.21
Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One (2013) 1.18
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol (2009) 1.13
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene (2007) 1.12
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol (2012) 1.05
Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch (2008) 1.01
Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer (2003) 0.97
Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol (2013) 0.96
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer (2006) 0.93
Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. J Biol Chem (2012) 0.91
Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol (2004) 0.91
Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol (2011) 0.90
Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol (2013) 0.88
Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol (2011) 0.88
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS One (2013) 0.86
Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol (2011) 0.86
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia (2010) 0.84
Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol (2013) 0.81
Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas. Neuro Oncol (2009) 0.81
A multi-resolution textural approach to diagnostic neuropathology reporting. J Neurooncol (2015) 0.80
Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology (2015) 0.78
Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status. Transl Oncol (2014) 0.78
Intraoperative diagnosis of glioblastomamultiforme with oligodendroglial and sarcomatous components. J Neurosci Rural Pract (2015) 0.75
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet (2005) 3.77
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 2.53
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology (2007) 2.52
Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature (1997) 2.44
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology (2010) 2.36
Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS) Am J Clin Pathol (1998) 2.35
HSV-1 in brain and risk of Alzheimer's disease. Lancet (1998) 2.21
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron (1990) 2.09
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol (1997) 1.79
Location score and haplotype analyses of the locus for autosomal recessive spastic ataxia of Charlevoix-Saguenay, in chromosome region 13q11. Am J Hum Genet (1999) 1.78
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 1.74
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73
MR appearance of hypertrophic olivary degeneration after contralateral cerebellar hemorrhage. AJNR Am J Neuroradiol (1991) 1.69
Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien) (2002) 1.67
Alzheimer's disease: current knowledge, management and research. CMAJ (1997) 1.66
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Fulminating multiple sclerosis-like leukoencephalopathy revealing human immunodeficiency virus infection. Neurology (1991) 1.56
The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci (2000) 1.56
Neurological complications of radiotherapy and chemotherapy. J Neurol (1998) 1.56
Supratentorial low-grade gliomas in older patients. Neurology (2009) 1.55
Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res (1995) 1.50
Facilitating submental endotracheal intubation with an endotracheal tube exchanger. Anesth Analg (2000) 1.49
Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology (2009) 1.48
Registered Replication Report: Schooler and Engstler-Schooler (1990). Perspect Psychol Sci (2014) 1.48
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol (1989) 1.45
[Benign intracranial hypertension and minocycline]. Rev Neurol (Paris) (1988) 1.42
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet (1985) 1.41
Unusual multicystic lesions of the brainstem are mesencephalo-thalamic expanding lacunae. Br J Neurosurg (1997) 1.40
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1998) 1.39
[Chronic meningitis before diagnosis of celiac disease]. Rev Neurol (Paris) (2002) 1.39
Atypical MR presentation of Wilson disease: a possible consequence of paramagnetic effect of copper? Neuroradiology (1992) 1.38
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 1.38
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: comparison with intraoperative stimulation in patients with brain tumors. J Neurosurg (2000) 1.35
Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer (1995) 1.35
Neurological complications of primary Sjögren's syndrome. J Neurol (2001) 1.34
Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol (2001) 1.34
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry (2005) 1.31
Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation. J Neurol Neurosurg Psychiatry (2003) 1.30
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J (2001) 1.29
Acute myeloradiculitis due to cytomegalovirus as the initial manifestation of AIDS. J Neurol Neurosurg Psychiatry (1989) 1.29
Intracranial extra-axial cavernous (HEM) angiomas: tumors or vascular malformations? J Neuroradiol (2002) 1.29
Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer (2007) 1.28
Vertebral hemangiomas presenting with neurologic symptoms. Surg Neurol (1987) 1.28
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology (2004) 1.27
Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus. Arch Neurol (2002) 1.26
[Ultrastructure of hem- angioblastomas of the central nervous system]. Rev Neurol (Paris) (1968) 1.25
Early rebleeding from intracranial dural arteriovenous fistulas: report of 20 cases and review of the literature. J Neurosurg (1999) 1.22